Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT07784270
Recruiting Phase 3

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

NCT07784270 · tracked via the Priya Life Science Spain tracker
Phase
Phase 3
Started
2026-08-20
Last updated
2026-09-22

Condition(s) studied

Obesity or OverweightDiabetes Mellitus, Type 2

Investigational drug(s) / intervention(s)

AZD6234 →Placebo

AZD6234: IMP injected subcutaneously, once a week. Unit dose strength as per CSP.

Placebo: Placebo matching IMP dose injected subcutaneously, once a week.

Study summary

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Males \& females (inclusive of all gender identities) age ≥18 years * BMI ≥27 kg/m2 * Diagnosed with T2DM ≥90 days prior to Screening * HbA1c value at Screening of ≥6.0% (42 mmol/mol) and ≤10% (86 mmol/mol) managed with diet and exercise alone or with a stable dose of any oral glycaemic-lowering agent (as per local labelling) * Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation * History of at least one self-reported unsuccessful attempt to lose body weight in lifetime Exclusion Criteria: * Obesity primarily caused by other endocrine disorders * Type 1 diabetes mellitus (or any other diabetes mellitus that is not clearly Type 2 diabetes), OR have history of ketoacidosis or hyperosmolar coma/state within 3 months prior to Screening * Significant hepatobiliary disease and/or any of the following results at Screening: * ALT ≥ 3.0 X ULN * AST ≥ 3.0 X ULN * TBL \> 1.5 X ULN (except for cases of known Gilbert's Syndrome) * Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation * Use of insulin therapy for T2DM within 3 months prior to screening

Primary outcome measure(s)

Trial sites (227)

FacilityCityRegionStatus
Research Site Fairhope Alabama Recruiting
Research Site Huntsville Alabama Not Yet Recruiting
Research Site Mobile Alabama Not Yet Recruiting
Research Site Mesa Arizona Not Yet Recruiting
Research Site Phoenix Arizona Not Yet Recruiting
Research Site Tucson Arizona Not Yet Recruiting
Research Site Little Rock Arkansas Not Yet Recruiting
Research Site Bakersfield California Not Yet Recruiting
Research Site Gardena California Not Yet Recruiting
Research Site Lincoln California Recruiting
Research Site Torrance California Not Yet Recruiting
Research Site Walnut Creek California Not Yet Recruiting
Research Site Coral Gables Florida Not Yet Recruiting
Research Site Fleming Island Florida Not Yet Recruiting
Research Site Fort Lauderdale Florida Not Yet Recruiting
Research Site Ocoee Florida Not Yet Recruiting
Research Site Woodstock Georgia Not Yet Recruiting
Research Site Chicago Illinois Not Yet Recruiting
Research Site Melrose Park Illinois Not Yet Recruiting
Research Site Lenexa Kansas Recruiting
Research Site Newton Kansas Not Yet Recruiting
Research Site Monroe Louisiana Not Yet Recruiting
Research Site Beltsville Maryland Not Yet Recruiting
Research Site Lanham Maryland Not Yet Recruiting
Research Site Oxon Hill Maryland Not Yet Recruiting
Research Site Rockville Maryland Not Yet Recruiting
Research Site North Dartmouth Massachusetts Not Yet Recruiting
Research Site Farmington Hills Michigan Not Yet Recruiting
Research Site Fayette Mississippi Not Yet Recruiting
Research Site Kansas City Missouri Not Yet Recruiting
Research Site Kansas City Missouri Not Yet Recruiting
Research Site St Louis Missouri Not Yet Recruiting
Research Site Omaha Nebraska Not Yet Recruiting
Research Site Omaha Nebraska Not Yet Recruiting
Research Site Eatontown New Jersey Not Yet Recruiting
Research Site Somerset New Jersey Not Yet Recruiting
Research Site Warren Township New Jersey Not Yet Recruiting
Research Site Greensboro North Carolina Withdrawn
Research Site Monroe North Carolina Not Yet Recruiting
Research Site Kent Ohio Not Yet Recruiting

+ 187 more sites — see the full list on the official registry below.

More AstraZeneca trials in Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07784270 on ClinicalTrials.gov ↗ ← All trials in Spain